<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2007-10-21" updated="2020-01-02">
  <drugbank-id primary="true">DB04950</drugbank-id>
  <name>Ranpirnase</name>
  <description>Ranpirnase is a ribonuclease enzyme found in &lt;i&gt;Rana pipiens&lt;/i&gt; oocytes. It is being studied in the treatment of cancer. It is manufactured by Alfacell Corporation. It is the first ribonuclease to enter cancer clinical trials.</description>
  <cas-number>196488-72-9</cas-number>
  <unii>ZE15FIT23E</unii>
  <state>solid</state>
  <groups>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A3038</ref-id>
        <pubmed-id>11561684</pubmed-id>
        <citation>Vogelzang NJ, Aklilu M, Stadler WM, Dumas MC, Mikulski SM: A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer. Invest New Drugs. 2001;19(3):255-60.</citation>
      </article>
      <article>
        <ref-id>A3039</ref-id>
        <pubmed-id>16548765</pubmed-id>
        <citation>Pavlakis N, Vogelzang NJ: Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther. 2006 Apr;6(4):391-9.</citation>
      </article>
      <article>
        <ref-id>A3040</ref-id>
        <pubmed-id>17324010</pubmed-id>
        <citation>Authors unspecified: Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D. 2007;8(2):120-4.</citation>
      </article>
      <article>
        <ref-id>A3041</ref-id>
        <pubmed-id>17352247</pubmed-id>
        <citation>Lee I, Kalota A, Gewirtz AM, Shogen K: Antitumor efficacy of the cytotoxic RNase, ranpirnase, on A549 human lung cancer xenografts of nude mice. Anticancer Res. 2007 Jan-Feb;27(1A):299-307.</citation>
      </article>
      <article>
        <ref-id>A3042</ref-id>
        <pubmed-id>18019404</pubmed-id>
        <citation>Lee I, Kim DH, Sunar U, Magnitsky S, Shogen K: The therapeutic mechanisms of ranpirnase-induced enhancement of radiation response on A549 human lung cancer. In Vivo. 2007 Sep-Oct;21(5):721-8.</citation>
      </article>
      <article>
        <ref-id>A3043</ref-id>
        <pubmed-id>16497678</pubmed-id>
        <citation>Suhasini AN, Sirdeshmukh R: Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem. 2006 May 5;281(18):12201-9. Epub 2006 Feb 23.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L73</ref-id>
        <title>Link</title>
        <url>http://www.wipo.int/pctdb/en/wo.jsp?WO=2004061120&amp;IA=WO2004061120&amp;DISPLAY=DESC</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of various forms of cancer.</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Ranpirnase controls tumour growth by degrading RNA within cancer cells, resulting in inhibition of protein synthesis and arresting mitosis in G(1)phase.</mechanism-of-action>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms/>
  <products/>
  <international-brands>
    <international-brand>
      <name>Onconase</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Egg Proteins</category>
      <mesh-id>D004527</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Enzymes</category>
      <mesh-id>D004798</mesh-id>
    </category>
    <category>
      <category>Enzymes and Coenzymes</category>
      <mesh-id>D045762</mesh-id>
    </category>
    <category>
      <category>Esterases</category>
      <mesh-id>D004950</mesh-id>
    </category>
    <category>
      <category>Hydrolases</category>
      <mesh-id>D006867</mesh-id>
    </category>
    <category>
      <category>Protein Synthesis Inhibitors</category>
      <mesh-id>D011500</mesh-id>
    </category>
    <category>
      <category>Rana pipiens</category>
      <mesh-id>D011894</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ranpirnase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ranpirnase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ranpirnase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ranpirnase.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347909856</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Ranpirnase</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0004796</id>
      <name>DNA</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A3040</ref-id>
            <pubmed-id>17324010</pubmed-id>
            <citation>Authors unspecified: Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell. Drugs R D. 2007;8(2):120-4.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>